Answers are grounded in this paper and cite their sources.
Population pharmacokinetic/pharmacodynamic modelling evaluates favipiravir's efficacy in COVID-19, suggesting limited antiviral effects.
Our findings suggest that favipiravir does not have antiviral activity at the dose used in our study, and further work to understand the mechanistic basis of the drug-drug interaction with lopinavir-ritonavir is required.
No takes yet. Share an insight, caveat, or question.
Agyeman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: